alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › opportunities

opportunities

4 studies tagged opportunities, dated 2015-01-29 to 2025-07-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges 2025-07-25
  2. Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force 2025-04-18
  3. Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development 2019-08-23

Studies

4 studies carry this tag.

Date range

2015 to 2025

Top journals

  • The journal of prevention of Alzheimer's disease 2
  • Expert review of molecular diagnostics 1
  • Frontiers in pharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journal of prevention of Alzheimer's disease 2025-07-25 Biomarkers

    Blood-based biomarkers (BBMs) for Alzheimer's disease (AD) have advanced rapidly and may be a critical tool for broad community-based screening for AD and detection of AD pathology in individuals with cognitive impairment.

  2. Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. The journal of prevention of Alzheimer's disease 2025-04-18 Drug development

    Following the recent approvals of anti-amyloid immunotherapies as "first-in-kind" disease-modifying agents for Alzheimer's disease (AD), there is an emerging emphasis in combination therapies, given the complex and multifactorial etiopathogenesis and pathophysiology of the disease.

  3. Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in pharmacology 2019-08-23 TREM2 and immune genetics

    Alzheimer's disease (AD) is a large and increasing unmet medical need with no disease-modifying treatment currently available.

  4. Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert review of molecular diagnostics 2015-01-29 Genetics

    Alzheimer's disease (AD), the most common form of dementia in western societies, is a pathologically and clinically heterogeneous disease with a strong genetic component.

All topic tags with their study counts